GNSZ News Wednesday, June 25, 2014 5:16:31 PM $GNS
Post# of 54
Posted On: 06/25/2014 6:16:26 PM
GNSZ News Wednesday, June 25, 2014 5:16:31 PM $GNSZ
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity
PR Newswire - Wed Jun 25, 7:15AM CDT
Biotech sector sees progress as companies develop advanced cancer therapeutics resulting in significant clinical data; company reaches agreement to develop drug aiding cancer treatment: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics Inc. (NASDAQ: SGEN), (Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), OXiGENE, Inc. (NASDAQ: OXGN) and MerriMack Pharmaceuticals, Inc. (NASDAQ: MACK)
GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202
PR Newswire - Tue Jun 24, 3:27PM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.
GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer"
PR Newswire - Mon Jun 23, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.
A New Breed of Targeted Cancer Therapeutics & Stem Cell Advancements; Effective ProDrug Therapeutics Approach for GenSpera
PR Newswire - Fri Jun 20, 7:29AM CDT
Healthcare industry update: companies develop advanced technologies and approaches for cancer treatment, clinical data reveals progress: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics, Inc. (NASDAQ: SGEN), OXiGENE, Inc. (NASDAQ: OXGN), Pfizer Inc. (NYSE: PFE), GlaxoSmithKline plc (NYSE: GSK) and StemCells Inc. (NASDAQ: STEM)
GenSpera CEO, Craig Dionne, to Present Update on Lead Drug Candidate G-202 at 2014 Bio International Convention
PR Newswire - Thu Jun 19, 7:00AM CDT
GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the 2014 BIO International Convention, on Tuesday, June 24th, at 11:15 PDT, in San Diego, CA (http://mybio.org/search/all?terms=GenSpera). Dr. Dionne will give an update of the ongoing G-202 Phase II trials in both hepatocellular carcinoma and glioblastoma patients and discuss upcoming milestones, as well as deliver a general GenSpera overview.
GenSpera Announces $3.33 Million Registered Public Offering
Business Wire - Thu May 29, 7:53AM CDT
GenSpera, Inc. (OTCQB:GNSZ) announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately $3.33 million units, in a registered public offering, at a price per unit of $0.80. Each unit consists of one share of common stock, one-half of a Series A warrant, one Series B warrant and one Series C warrant. The Series A warrants will be exercisable into approximately 2.1 million shares of the company's common stock at an exercise price of $1.15 per share, are exercisable immediately and have a term of exercise equal to five years. The Series B warrants will be exercisable into approximately 4.2 million shares of the company's common stock at an exercise price of $0.85, are exercisable immediately and have a term of exercise of 9 months. The Series C warrants will be exercisable into approximately 4.2 million shares of the company's common stock at an exercise price of $0.85, are immediately exercisable and have a term of exercise of one year. The anticipated closing of the offering is expected on or about June 3, 2014, subject to satisfaction of customary closing conditions.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:
First Patient Enrolled in GenSpera G-202 Phase II Glioblastoma Trial
Business Wire - Tue Mar 18, 7:02AM CDT
GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer. The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.
GenSpera CEO, Craig Dionne, to Present at BIO CEO & Investor Conference, February 10th
Business Wire - Thu Feb 06, 8:02AM CST
GenSpera, Inc. (OTCQB:GNSZ) announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO CEO & Investor Conference 2014, on Monday, February 10th, at 1:30 PM. The conference is taking place at the Waldorf Astoria Hotel in New York, NY.
GenSpera Announces $5 Million in Private Financing
Business Wire - Mon Aug 19, 7:09AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced today it has entered into subscription agreements with accredited investors and qualified institutional buyers totaling approximately $5 million, in which the purchasers are acquiring 3,333,373 units for $1.50 per unit. GenSpera expects this offering to close on Monday, August 19, 2013. T.R. Winston & Company, LLC acted as Placement Agent for the offering.
OTC Daily Alert Stock Watch - GenSpera (OTCBB:GNSZ)
WorldStockWire - Tue Aug 13, 6:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013
M2 - Fri Aug 02, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8c4tpq/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. - A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - AstraZeneca PLC - Eli Lilly and Company - Genentech, Inc. - Bavarian Nordic A/S - Merck & Co., Inc. - Emergent BioSolutions Inc. - Takeda Pharmaceutical Company Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - GTx, Inc. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Exelixis, Inc. - Aduro BioTech - Merck KGaA - Active Biotech AB - Oncolytics Biotech Inc. - Oncothyreon Inc - Osta Biotechnologies Inc. - Medivation, Inc. - Synta Pharmaceuticals Corp. - Supratek Pharma Inc. - CellCentric Ltd. - CureVac GmbH - GenSpera, Inc. - BIND Biosciences, Inc. - NewLink Genetics Corporation - Bellicum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8c4tpq/metastatic
GenSpera Receives Patent on Targeted Prostate Cancer Drugs
Business Wire - Thu Jun 06, 7:02AM CDT
GenSpera, Inc. (OTC.BB: GNSZ) announced that the United States Patent and Trademark Office (USPTO) issued patent 8,450,280 "Activation of Peptide Prodrugs by HK2." The patent covers the composition of a series of prodrugs activated by HK2 to deliver a thapsigargin derivative selectively to prostate cancers. HK2 is an enzyme secreted by prostate cancer cells. A derivative of thapsigargin, 12ADT, is the active component of G-202, GenSpera's lead drug candidate in Phase II clinical trials for liver cancer after sorafenib (Nexavar(R)) therapy.
GenSpera Chief Executive Officer Craig Dionne to Present to BIO Business Forum(TM) on April 23, 2013 in Chicago
Business Wire - Wed Apr 10, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) today announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO Business Forum(TM) on Tuesday, April 23, 2013, at 10:30 AM CDT. The forum is held from April 22-25 in conjunction with the 2013 BIO International Convention, the largest international event for the biotech industry, at McCormick Place in Chicago, Illinois.
GenSpera's G-202 Granted U.S. Orphan Drug Designation for Treatment of Hepatocellular Carcinoma
Business Wire - Thu Mar 14, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to its lead candidate, G-202, for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. G-202 is currently in a Phase II clinical trial for patients with hepatocellular carcinoma whose disease has worsened on standard therapy for this indication.
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma Trial
Business Wire - Thu Feb 21, 7:02AM CST
GenSpera, Inc. (OTCBB:GNSZ) announced that the first patient has been treated in the Phase II clinical trial of its lead compound, G-202, in patients who have hepatocellular carcinoma (HCC).
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity
PR Newswire - Wed Jun 25, 7:15AM CDT
Biotech sector sees progress as companies develop advanced cancer therapeutics resulting in significant clinical data; company reaches agreement to develop drug aiding cancer treatment: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics Inc. (NASDAQ: SGEN), (Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), OXiGENE, Inc. (NASDAQ: OXGN) and MerriMack Pharmaceuticals, Inc. (NASDAQ: MACK)
GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202
PR Newswire - Tue Jun 24, 3:27PM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.
GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer"
PR Newswire - Mon Jun 23, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.
A New Breed of Targeted Cancer Therapeutics & Stem Cell Advancements; Effective ProDrug Therapeutics Approach for GenSpera
PR Newswire - Fri Jun 20, 7:29AM CDT
Healthcare industry update: companies develop advanced technologies and approaches for cancer treatment, clinical data reveals progress: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics, Inc. (NASDAQ: SGEN), OXiGENE, Inc. (NASDAQ: OXGN), Pfizer Inc. (NYSE: PFE), GlaxoSmithKline plc (NYSE: GSK) and StemCells Inc. (NASDAQ: STEM)
GenSpera CEO, Craig Dionne, to Present Update on Lead Drug Candidate G-202 at 2014 Bio International Convention
PR Newswire - Thu Jun 19, 7:00AM CDT
GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the 2014 BIO International Convention, on Tuesday, June 24th, at 11:15 PDT, in San Diego, CA (http://mybio.org/search/all?terms=GenSpera). Dr. Dionne will give an update of the ongoing G-202 Phase II trials in both hepatocellular carcinoma and glioblastoma patients and discuss upcoming milestones, as well as deliver a general GenSpera overview.
GenSpera Announces $3.33 Million Registered Public Offering
Business Wire - Thu May 29, 7:53AM CDT
GenSpera, Inc. (OTCQB:GNSZ) announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately $3.33 million units, in a registered public offering, at a price per unit of $0.80. Each unit consists of one share of common stock, one-half of a Series A warrant, one Series B warrant and one Series C warrant. The Series A warrants will be exercisable into approximately 2.1 million shares of the company's common stock at an exercise price of $1.15 per share, are exercisable immediately and have a term of exercise equal to five years. The Series B warrants will be exercisable into approximately 4.2 million shares of the company's common stock at an exercise price of $0.85, are exercisable immediately and have a term of exercise of 9 months. The Series C warrants will be exercisable into approximately 4.2 million shares of the company's common stock at an exercise price of $0.85, are immediately exercisable and have a term of exercise of one year. The anticipated closing of the offering is expected on or about June 3, 2014, subject to satisfaction of customary closing conditions.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:
First Patient Enrolled in GenSpera G-202 Phase II Glioblastoma Trial
Business Wire - Tue Mar 18, 7:02AM CDT
GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer. The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.
GenSpera CEO, Craig Dionne, to Present at BIO CEO & Investor Conference, February 10th
Business Wire - Thu Feb 06, 8:02AM CST
GenSpera, Inc. (OTCQB:GNSZ) announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO CEO & Investor Conference 2014, on Monday, February 10th, at 1:30 PM. The conference is taking place at the Waldorf Astoria Hotel in New York, NY.
GenSpera Announces $5 Million in Private Financing
Business Wire - Mon Aug 19, 7:09AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced today it has entered into subscription agreements with accredited investors and qualified institutional buyers totaling approximately $5 million, in which the purchasers are acquiring 3,333,373 units for $1.50 per unit. GenSpera expects this offering to close on Monday, August 19, 2013. T.R. Winston & Company, LLC acted as Placement Agent for the offering.
OTC Daily Alert Stock Watch - GenSpera (OTCBB:GNSZ)
WorldStockWire - Tue Aug 13, 6:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013
M2 - Fri Aug 02, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8c4tpq/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. - A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - AstraZeneca PLC - Eli Lilly and Company - Genentech, Inc. - Bavarian Nordic A/S - Merck & Co., Inc. - Emergent BioSolutions Inc. - Takeda Pharmaceutical Company Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - GTx, Inc. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Exelixis, Inc. - Aduro BioTech - Merck KGaA - Active Biotech AB - Oncolytics Biotech Inc. - Oncothyreon Inc - Osta Biotechnologies Inc. - Medivation, Inc. - Synta Pharmaceuticals Corp. - Supratek Pharma Inc. - CellCentric Ltd. - CureVac GmbH - GenSpera, Inc. - BIND Biosciences, Inc. - NewLink Genetics Corporation - Bellicum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8c4tpq/metastatic
GenSpera Receives Patent on Targeted Prostate Cancer Drugs
Business Wire - Thu Jun 06, 7:02AM CDT
GenSpera, Inc. (OTC.BB: GNSZ) announced that the United States Patent and Trademark Office (USPTO) issued patent 8,450,280 "Activation of Peptide Prodrugs by HK2." The patent covers the composition of a series of prodrugs activated by HK2 to deliver a thapsigargin derivative selectively to prostate cancers. HK2 is an enzyme secreted by prostate cancer cells. A derivative of thapsigargin, 12ADT, is the active component of G-202, GenSpera's lead drug candidate in Phase II clinical trials for liver cancer after sorafenib (Nexavar(R)) therapy.
GenSpera Chief Executive Officer Craig Dionne to Present to BIO Business Forum(TM) on April 23, 2013 in Chicago
Business Wire - Wed Apr 10, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) today announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO Business Forum(TM) on Tuesday, April 23, 2013, at 10:30 AM CDT. The forum is held from April 22-25 in conjunction with the 2013 BIO International Convention, the largest international event for the biotech industry, at McCormick Place in Chicago, Illinois.
GenSpera's G-202 Granted U.S. Orphan Drug Designation for Treatment of Hepatocellular Carcinoma
Business Wire - Thu Mar 14, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to its lead candidate, G-202, for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. G-202 is currently in a Phase II clinical trial for patients with hepatocellular carcinoma whose disease has worsened on standard therapy for this indication.
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma Trial
Business Wire - Thu Feb 21, 7:02AM CST
GenSpera, Inc. (OTCBB:GNSZ) announced that the first patient has been treated in the Phase II clinical trial of its lead compound, G-202, in patients who have hepatocellular carcinoma (HCC).
(0)
(0)Rebus Hldgs (RBSH) Stock Research Links
Scroll down for more posts ▼